Roles of dextrans on improving lymphatic drainage for liposomal drug delivery system

Journal of Drug Targeting

Volumn 18, Issue 3, 2010, Pages 168-178

  Feng, Linglin ^a,b   Zhang, Lei ^a   Liu, Min ^a   Yan, Zhiqiang ^a   Wang, Chenyu ^a   Gu, Bing ^a   Liu, Yu ^a   Wei, Gang ^a   Zhong, Gaoren ^a   Lu, Weiyue ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

Dextrans; Diethylaminoethyl dextran; Drainage; Liposomes; Local tissue damage; Lymphatic targeted

Indexed keywords

DIETHYLAMINOETHYLDEXTRAN; DOXORUBICIN; LIPOSOME; RHODAMINE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG UPTAKE; INJECTION SITE; ISOTOPE LABELING; LIPOSOMAL DELIVERY; LYMPH NODE; LYMPHATIC DRAINAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; RAT; SYSTEMIC CIRCULATION; TARGET ORGAN; TISSUE INJURY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DEAE-DEXTRAN; DEXTRANS; DOXORUBICIN; DRAINAGE; DRUG DELIVERY SYSTEMS; LIPOSOMES; LYMPH NODES; MACROPHAGES; MALE; MICE; MICROSCOPY, CONFOCAL; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINES;

EID: 77949360514     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903318126     Document Type: Article

References (34)

1. Averbuch SD, Gaudiano G, Koch TH, Bachur NR. 1986. Doxorubicininduced skin necrosis in the swine model: protection with a novel radical dimer. ed. p 88-94.
2. Bartlett GR. (1959). Phosphorus assay in column chromatography. J Biol Chem, 234, 466-468.
3. Boman NL, Tron VA, Bally MB, Cullis PR. (1996). Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemotherapy and Pharmacology, 37, 351-355.
4. Eckelman WC, Karesh SM, Reba RC. (1975). New compounds: fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent. J Pharm Sci, 64, 704-706.
5. Forssen EA, Tokes ZA. (1983). Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep, 67, 481-484.
6. Fujiwara M, Baldeschwieler JD, Grubbs RH. (1996). Receptormediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1278, 59-67.
7. Gbadamosi JK, Hunter AC, Moghimi SM. (2002). PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Letters, 532, 338-344.
8. Grant CW, Karlik S, Florio E. (1989). A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med, 11, 236-243.
9. Gregoriadis G. (2008). Liposome research in drug delivery: the early days. J Drug Target, 16, 520-524.
10. Hawley AE, Davis SS, Illum L. (1995). Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Advanced Drug Delivery Reviews, 17, 129-148.
11. Kaur Chanchal D, Nahar M, Jain Narendra K. (2008). Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target, 16, 798-805.
12. Khato J, Priester ER, Sieber SM. (1982). Enhanced lymph node uptake of melphalan following liposomal entrapment and effects on lymph node metastasis in rats. Cancer Treat Rep, 66, 517-527.
13. Liu M, Pan J, Yao M, Zhou GX, Lu WY. (2007). In vivo antitumor effect of folate stealth liposomes load with doxorubicin in HeLa229 carcinoma nude mice model. Chinese Journal of Pharmaceuticals, 38, 97-101.
14. Ma YM, Lu WY, Jiang CY, Liu YC. (1997). Studies on two new lymph imaging agents and their clinical application. Advanced Drug Delivery Reviews, 24, 315-323.
15. Mathias CJ, Hubers D, Low PS, Green MA. (2000). Synthesis of [(99m) Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem, 11, 253-257.
16. McLennan DN, Porter CJH, Charman SA. (2005). Subcutaneous drug delivery and the role of the lymphatics. Drug Discovery Today: Technologies, 2, 89.
17. Moghimi M, Moein Moghimi S. (2008). Lymphatic targeting of immuno-PEG-liposomes: Evaluation of antibody-coupling procedures on lymph node macrophage uptake. J Drug Targeting, 16, 586-590.
18. Moghimi SM. (2003). Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Letters, 540, 241-244.
19. Moghimi SM, Hawley AE, Christy NM, Gray T, Illum L, Davis SS. (1994). Surface Engineered Nanospheres with Enhanced Drainage into Lymphatics and Uptake by Macrophages of the Regional Lymph-Nodes. Febs Letters, 344, 25-30.
20. Oussoren C, Eling WMC, Crommelin DJA, Storm G, Zuidema J. (1998a). The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochimica et Biophysica Acta, Biomembranes, 1369, 159-172.
21. Oussoren C, Storm G. (2001). Liposomes to target the lymphatics by subcutaneous administration. Advanced Drug Delivery Reviews, 50, 143-156.
22. Oussoren C, Velinova M, Scherphof G, van der Want JJ, van Rooijen N, Storm G. (1998b). Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: IV. Fate of liposomes in regional lymph nodes. Biochimica et Biophysica Acta (BBA) -Biomembranes, 1370, 259.
23. Paik CH, Ebbert MA, Murphy PR, Lassman CR, Reba RC, Eckelman WC, Pak KY, Powe J, Steplewski Z, Koprowski H. (1983). Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med, 24, 1158-1163.
24. Pan H, Han L, Chen W, Yao M, Lu W. (2008). Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. Journal of Controlled Release, 125, 228-235.
25. Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. (1992). A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Nuclear Medicine and Biology, 19, 539-547.
26. Rao DA, Robinson JR. (2008). Effect of size and surface properties of biodegradable PLGA-PMA: PLA:PEG nanoparticles on lymphatic uptake and retention in rats. Journal of Controlled Release, 132, e45-e47.
27. Schmid-Schonbein GW. 1990. Microlymphatics and lymph flow. Physiological Reviews, ed. p 987-1028.
28. Slauson DO, Lay JC, Castleman WL, Neilsen NR. (1989). Influence of acute pulmonary interstitial Inflammation on kinetics of phagocytosis by alveolar macrophages. Inflammation FIELD Full Journal Title:Inflammation, 13, 429-441.
29. Spiegel RJ. (1981). The acute toxicities of chemotherapy. Cancer Treat Rev, 8, 197-207.
30. Strand SE, Bergqvist L. (1989). Radiolabeled colloids and macromolecules in the lymphatic system. Crit Rev Ther Drug Carrier Syst, 6, 211-238.
31. Swartz MA. (2001). The physiology of the lymphatic system. Advanced Drug Delivery Reviews, 50, 3-20.
32. Trubetskoy VS, Whiteman KR, Torchilin VP, Wolf GL. (1998). Massage-induced release of subcutaneously injected liposome-encapsulated drugs to the blood. J Control Release, 50, 13-19.
33. van Rooijen N. (2008). Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages. J Drug Target, 16, 529-534.
34. Yang GC, Brooks JJ, Roberts S, Gupta PK. (1993). The detection of acquired immunodeficiency syndrome-associated Kaposi sarcoma cells in pleural effusion by CD34 immunostain. Cancer, 72, 2260-2265.